Frequency, Characteristics, Management, and Outcomes of Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Multicentre Retrospective Study of the Turkish Pediatric BMT Study Group
Authors:
- Fatih ErbeyFEFatih Erbey
- Musa KarakükcüMKMusa Karakükcü
- Gülcihan ÖzekGÖGülcihan Özek
- Ebru YılmazEYEbru Yılmaz
- Serap AksoylarSASerap Aksoylar
- Ülker KoçakÜKÜlker Koçak
- Vedat UygunVUVedat Uygun
- Barış MalboraBMBarış Malbora
- Safiye Suna ÇelenSÇSafiye Suna Çelen
- Alper ÖzcanAÖAlper Özcan
- Arzu AkyayAAArzu Akyay
- Funda Tayfun KüpesizFKFunda Tayfun Küpesiz
Open Access
- 4 March 2026
- journal article
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 139-147
Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a rare yet potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). This study aimed to determine the incidence, clinical features, management strategies, and prognostic factors influencing outcomes of PTLD after allogeneic HSCT in children. Data were retrospectively collected from 15 pediatric centers performing allogeneic HSCT between June 2010 and May 2025. Clinical features, treatment approaches and outcomes of the cases were analyzed. During the study period, 6129 children underwent allogeneic HSCT, and 34 (0.56%) developed PTLD. The median interval between HSCT and PTLD diagnosis was 197 days, with the majority of cases occurring within the first post-transplant year. At diagnosis, gastrointestinal involvement was observed in 22 patients (64.7%), cytopenia in 17 (50%), central nervous system (CNS) involvement in 7 (20.5%), pulmonary involvement in 6 (17.6%), and macrophage activation syndrome in 4 (11.7%). Rituximab-based therapy was administered to 29 patients (85.3%), and immunosuppression was reduced in 25 (73.5%). Mortality was significantly higher among patients presenting with CNS involvement (4 of 7, 57.1%; p < 0.05). Treatment response was also affected the prognosis, among 27 patients who achieved remission, 25 survived (92.6%), compared to only 1 of 7 (14.3%) non-responders (p < 0.05). The overall PTLD-related mortality rate was 17.6% (6 patients). Median follow-up among survivors was 43 months, with a 5-year overall survival rate of 76.5%. PTLD occurred infrequently among pediatric allogeneic HSCT recipients. CNS involvement and failure to achieve remission were strongly associated with poorer overall survival.Keywords
This publication has 28 references indexed in Scilit:
- Prospective Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first‐line treatmentTransplant Infectious Disease, 2016
- Establishment and operation of a Good Manufacturing Practice‐compliant allogeneic Epstein‐Barr virus (EBV)‐specific cytotoxic cell bank for the treatment of EBV‐associated lymphoproliferative diseaseBritish Journal of Haematology, 2014
- Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationClinical Infectious Diseases, 2013
- Prognostic factors and outcome of Epstein–Barr virus DNAemia in high‐risk recipients of allogeneic stem cell transplantation treated with preemptive rituximabTransplant Infectious Disease, 2013
- Low-Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children’s Oncology Group ReportAmerican Journal of Transplantation, 2012
- A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell TransplantationTransplantation, 2010
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsBlood, 2010
- Outcome of treatment of Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported casesTransplant Infectious Disease, 2009
- Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS LymphomaJournal of Clinical Oncology, 2007
- Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.1999